Fierce Pharma4h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Fierce Pharma7h
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
Fierce Pharma14h
Inizio Evoke alums flex healthcare marketing prowess with launch of new agency
A group of former leaders from health comms giant Inizio Evoke have come together to launch Flex Marketing, a new agency ...
Fierce Pharma14h
Moderna shoulders $238M contract manufacturing cancellation charge in Q4
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
Fierce Pharma15h
Fierce Pharma Asia—Astellas' investment focus; Mitsubishi Tanabe's buyout; Leqembi's 'expansion phase'
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Fierce Pharma16h
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
Fierce Pharma16h
A heartwarming roundup of cardiovascular news and most-loved stories
Valentine’s Day represents a perfect opportunity to highlight news and updates from across biopharma that have hearts a | ...
Fierce Pharma17h
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...